The use of high-throughput sequencing (HTS) to identify viral contamination of biological products is extremely sensitive and provides a broad range of detection. PathoQuest, our strategic partner for HTS, has developed a new approach to differentiate inert versus active viral sequences to assist customers with de-risking the production process. It enables the ability to identify newly synthesized RNAs, an unequivocal sign of the presence of a transcriptionally active virus.
This game-changing methodology also improves the sensitivity and specificity of detecting adventitious viruses, in turn decreasing the overall time needed for viral testing and reducing the time required to achieve a marketable product. HTS can be validated in line with GLP and GMP requirements, is applicable to cell banks, cell therapy drug products, vaccines, and raw materials, and also has industrial application for virus inactivation testing and testing for the lack of replication-competent viruses in vector stocks.
View this webinar to learn how this new testing approach can help identify adventitious viruses in biologics.
Marc Eloit, DVM, PhD
Pathogen Discovery Laboratory Institut Pasteur
& PathoQuest Founder